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Abstract
Introduction: Triple-negative breast cancers (TNBCs) are characterised by lack of expression of hormone receptors
and epidermal growth factor receptor 2 (HER-2). As they frequently express epidermal growth factor receptors
(EGFRs), anti-EGFR therapies are currently assessed for this breast cancer subtype as an alternative to treatments
that target HER-2 or hormone receptors. Recently, EGFR-activating mutations have been reported in TNBC
specimens in an East Asian population. Because variations in the frequency of EGFR-activating mutations in East
Asians and other patients with lung cancer have been described, we evaluated the EGFR mutational profile in
tumour samples from European patients with TNBC.
Methods: We selected from a DNA tumour bank 229 DNA samples isolated from frozen, histologically proven and
macrodissected invasive TNBC specimens from European patients. PCR and high-resolution melting (HRM) analyses
were used to detect mutations in exons 19 and 21 of EGFR. The results were then confirmed by bidirectional
sequencing of all samples.
Results: HRM analysis allowed the detection of three EGFR exon 21 mutations, but no exon 19 mutations. There
was 100% concordance between the HRM and sequencing results. The three patients with EGFR exon 21 abnormal
HRM profiles harboured the rare R836R SNP, but no EGFR-activating mutation was identified.
Conclusions: This study highlights variations in the prevalence of EGFR mutations in TNBC. These variations have
crucial implications for the design of clinical trials involving anti-EGFR treatments in TNBC and for identifying the
potential target population.
Introduction
Triple-negative breast cancers (TNBCs), which are
defined by the lack of oestrogen receptor (ER), proges-
terone receptor (PR) and human epidermal growth fac-
tor receptor 2 (HER-2) expression, account for
approximately 15% of all breast carcinomas [1]. TNBCs
occur most frequently in young women and tend to
have more aggressive, metastatic behaviour and a worse
prognosis than other breast cancers. New systemic
therapies are urgently needed, as most patients experi-
ence TNBC relapse with distant metastases. In addition,
hormonal therapies and HER-2-targeted agents are inef-
fective in this group of patients because of the lack of
expression of these therapeutic targets in tumour cells.
Currently, chemotherapy is the only systemic therapeu-
tic option for this type of tumour. Despite the recent
breakthrough related to the development of poly(ADP-
ribose) polymerase inhibitors [2], sustained remission in
advanced TNBC is rare and additional targeted therapies
are crucially needed.
The receptor tyrosine kinase epidermal growth factor
receptor (EGFR) is frequently (30% to 52%) expressed in
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TNBC [3] and is associated with poor prognosis [4-6].
However, the results of clinical trials on the role of anti-
EGFR targeted therapies in this setting remain disap-
pointing [7-11]. Work on the response of non-small-cell
lung cancer (NSCLC) to anti-EGFR therapies suggests
that EGFR expression detected by immunohistochemis-
try (IHC) is not the best indicator of tumour-cell depen-
dence on EGFR [12]. Conversely, the presence of EGFR-
activating mutations is highly predictive of response to
treatment with gefitinib or erlotinib [13,14]. These
mutations are usually exon 19 deletions and the L858R
substitution in exon 21, as well as, rarely, exon 18 muta-
tions. They cluster around the ATP-binding pocket of
the tyrosine kinase domain of EGFR, leading to ligand-
independent activation of the receptor and longer acti-
vation time compared to wild-type EGFR. Exon 20
mutations, however, are associated with resistance to
anti-EGFR therapies [13-17].
EGFR mutations that may predict sensitivity to EGFR
inhibitors have been identified in TNBC as well. Teng
and collaborators [18] recently reported that 11.4% of
their TNBC series harboured EGFR exon 19 or 21
mutations. Because the frequency of EGFR-activating
mutations in Asian and European patients with NSCLC
is quite different [19-21], however, it is important to
validate these results in a European population of
patients with TNBC before considering the worldwide
potential of developing anti-EGFR targeted therapies in
TNBC patients.
Materials and methods
Patients and tumour samples
A total of 1,695 consecutive patients with breast cancer
referred to the Val d’Aurelle Cancer Centre between
2002 and 2010 were prospectively entered into the data-
base of a tumour DNA bank. The stored DNA was iso-
lated (see below) from frozen, histologically proven and
macrodissected invasive breast cancer specimens that
were handled primarily for ER and PR testing by using
the dextran charcoal method as previously described
[22,23]. Most of the tumour samples dedicated to mole-
cular analysis were selected on the basis of the immedi-
ate diagnosis by using frozen sections. Moreover,
additional tumour tissue samples were chosen following
the definitive histological diagnosis (with quantification
of the percentage of tumour cells) and grade assessment
after fixation. This was possible because frozen and for-
malin-fixed tumour tissue samples were selected from
the same tumour areas. Only samples in which at least
50% of tumour cells observed were used for further ana-
lysis for EGFR mutations. Tumours were considered ER-
and PR-positive when the receptor concentration was
higher than 10 fM/mg of protein or more than 10%
tumour cells were stained by IHC. Patients with primary
HER-2-negative breast cancer were initially selected
based on the level of HER-2 protein expression by IHC
using the A485 monoclonal antibody (Dako A/S,
Glostrup, Denmark). HER-2 scores of 0 and 1+ were
considered negative. Gene amplification was evaluated
using fluorescence in situ hybridisation or chromogenic
in situ hybridisation for HER-2 score 2+ tumours as
assessed by IHC. HER2 3+ scores were considered posi-
tive. A total of 229 DNA samples from TNBCs (ER-,
PR- and HER-2-negative) were ultimately selected for
this study. This study was reviewed and approved by
our Institutional Review Board. All patients gave their
written informed consent.
DNA extraction
Each frozen tumour specimen was pulverised in liquid
nitrogen with an automatic grinder (Cryobroyeur 2000P
Automatique; Rivoire, Montpellier, France), homoge-
nised in a Polytron homogeniser (Brinkmann Scientific
Instruments, Inc, Westbury, NY, USA) with buffer (20
mM Tris·HCI, 1.5 mM ethylenediaminetetraacetic acid
(EDTA), 10 mM Na2MoO4, 1.5 mM dithiothreitol, 10%
glycerol, pH 7.4) (buffer-to-tissue ratio 10:1 (vol/wt))
and centrifuged at 10,000 × g for 15 minutes. Total
genomic DNA was extracted from the pellet using the
QIAamp DNA Mini Kit (51304; QIAGEN, Hilden, Ger-
many) according to the manufacturer’s protocol. DNA
yield and purity were quantitated and assessed by mea-
suring the absorbance at 260 nm and 280 nm with a
NanoDrop spectrophotometer (Thermo Fisher Scientific,
Waltham, MA, USA). All samples had a 260-nm to 280-
nm ratio higher than 1.7. DNA was stored at -20°C in
Tris-EDTA buffer (10 mM Tris and 0.5 mM EDTA, pH
7.6).
PCR amplification and high-resolution melting analysis
PCR amplification and high-resolution melting (HRM)
analysis were performed on a Rotor-Gene 6000™ (Cor-
bett Life Science, Mortlake, NSW, Australia) using the
LightCycler 480 High Resolution Melting PCR Master
Mix kit (04 909 631 001; Roche Diagnostics, Meylan,
France). Primers were designed to amplify EGFR frag-
ments that span the region in which the exon 19 dele-
tions (182-bp amplicon) and the L858R mutation in
exon 21 (164-bp amplicon) are localised (Table 1). PCR
amplifications were performed in a final volume of 20 μl
that included 10 ng of purified genomic DNA, 10 μl of
2 × PCR mix, 2.4 μl of 25 mM MgCl2 and 0.4 μl of
each 10 μM forward and reverse primer. The following
cycling conditions were used: one cycle of 95°C for 5
minutes; then 50 cycles of 95°C for 15 seconds, 63°C to
58°C for 15 seconds (with a decrease in annealing tem-
perature of 0.5°C per cycle during the first 11 cycles),
72°C for 20 seconds; then one cycle of 95°C for 1
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minute, 40°C for 1 minute, 65°C for 20 seconds, and
finally a melt from 65°C to 95°C rising at a rate of 0.1°C
per 2 seconds. The melting conditions included one
cycle at 95°C for 1 minute, one cycle at 40°C for 1 min-
ute and one cycle at 65°C for 2 seconds, followed by a
melt from 65°C to 95°C rising at a rate of 0.1°C/second.
HRM data were analysed using Rotor-Gene 6000 version
1.7 software (Corbett Life Science). For each sample, the
normalised melting curves were evaluated and samples
were compared with a control consisting of genomic
DNA from the LNCaP cell line (wild-type EGFR) in a
deduced difference plot. Significant deviations from the
horizontal line relative to the spread of the wild-type
control were indicative of sequence changes within the
analysed amplicon. Genomic DNA from SW620 cells
was used as a second wild-type EGFR control, whereas
DNA from the H1650 and H1975 human NSCLC cell
lines was used as positive controls for EGFR exon 19
and exon 21 heterozygous mutations, respectively.
Water was used as a negative control for PCR
contamination.
DNA sequencing
After HRM analysis, PCR products were purified using
the ExoSAP-IT PCR Purification Kit (US78200; GE
Healthcare, Saclay, France) according to the manufac-
turer’s instructions. Purified PCR products were then
used as templates for sequencing with the BigDye Ter-
minator version 1.1 Cycle Sequencing Kit (4336774;
Applied Biosystems, Inc, Foster City, CA, USA). Reac-
tions were run on a Mastercycler gradient thermal
cycler (Eppendorf, Lepecq, France) according to the fol-
lowing protocol: one cycle of 96°C for 2 minutes; then
25 cycles of 96°C for 10 seconds, 50°C for 5 seconds
and 60°C for 2 minutes. 50°C for 5 seconds and 60°C
for 2 minutes. Purification was carried out using the
BigDye XTerminator Purification Kit (4376486; Applied
Biosystems, Inc). For all samples, bidirectional sequen-
cing was performed by using PCR primers and an
Applied Biosystems 3730xl DNA Analyzer. After migra-
tion completion, the EGFR sequences were analysed
using Applied Biosystems Sequencing Analysis version
5.2 software. Genomic DNA from LNCaP and SW620
cells (wild-type EGFR) was used as a negative control
and genomic DNA from H1650 and H1975 cells was
used as a positive control for exon 19
(c.2235_2249del15, p.E746_A750del) and exon 21
(c.2573T > G, p.L758R) mutations, respectively.
Results
Patient and tumour characteristics
A total of 229 DNA samples from TNBC tissue speci-
mens that contained a high percentage of tumour tissue
as required for ER and PR testing were selected for this
study. The main clinicopathological characteristics of
the patients with TNBC are summarised in Table 2. The
patients’ median age was 58 years (range, 29 to 84
years). Ductal carcinoma was the prevalent histological
type (79%). Eighteen patients were noted as no clinical
data regarding nodal metastatic spreading because the
sample used for DNA extraction was obtained during
the surgical removal of a local recurrence in individuals
who had had a previous lymphadenectomy (14 cases) or
a previous metastasectomy for distant recurrence (4
cases). Only nine tumours (4%) were classified as Scarff-
Bloom-Richardson grade 1.
Assay validation and sensitivity testing
First, genomic DNA from the H1650 and H1975
NSCLC cell lines with known EGFR mutations was used
to test the HRM mutation detection method. In the
deduced difference plot, the heteroduplex melting pat-
terns of the two cell lines were unambiguously different
from the curves of control LNCaP and SW620 cells
(wild-type EGFR). The two wild-type controls had com-
parable HRM curves (greater than 99% homology). The
sensitivity of the HRM mutation detection method with
the EGFR exon 19 and exon 21 primer pairs was tested
by using serial dilutions of genomic DNA from H1650
(exon 19 deletion) and H1975 (L858R substitution in
exon 21) cells in wild-type DNA to obtain proportions
of 50%, 25%, 10%, 5% and 2% of mutant DNA. For both
Table 1 Primer sequencesa
GenBank accession
number
Gene name and
primer
Sequence 5’-3’ Size
(nt)
GC
(%)
Amplicon
(bp)
Annealing
temperature
NM_005228 EGFR
Exon 19 forward
CGTCTTCCTTCTCTCTCTGTCATAGG 26 50% 182 58°C
EGFR
Exon 19 reverse
AAAAGGTGGGCCTGAGGTTC 20 55%
EGFR
Exon 21 forward
TTGGAGGACCGTCGCTTG 18 61.1% 164 58°C
EGFR
Exon 21 reverse
ACCTAAAGCCACCTCCTTACTTTG 24 45.8%
aEGFR = epidermal growth factor receptor; GC = percentage of guanines and cytosines in the primers’ sequence; nt = nucleotide.
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Table 2 Patient and tumour characteristicsa
Patient and tumour characteristics Number of patients (%)
(N = 229)
Patient age
Median age at diagnosis, years [range] 58 [29 to 84]
Tumour classification
T1 88 (38)
T2 109 (48)
T3 9 (4)
T4 21 (9)
TX 2 (1)
Node classification
N0 136 (59)
N1 47 (21)
N2 20 (9)
N3 8 (3)
NX 18 (8)
Metastasis classification
M0 212 (92)
M1 13 (6)
MX 4 (2)
Histology
Ductal 180 (79)
Lobular 14 (6)
Otherb 35 (15)
SBR grade
I 9 (4)
II 70 (31)
III 146 (64)
NE 4 (2)
Tubule formation
1 5 (2)
2 31 (14)
3 178 (78)
NE 15 (6.55)
Nuclear pleomorphism
1 5 (20)
2 66 (29)
3 102 (44)
NE 16 (7)
Mitotic count
1 45 (20)
2 66 (29)
3 102 (44)
NE 16 (7)
Peritumoural vascular invasion
Yes 115 (50)
No 53 (23)
NE 61 (27)
aMX = no clinical data regarding metastatic spreading; NE = not evaluated; NX = no clinical data regarding nodal status; TX = no clinical data regarding tumour
size. bNine undifferentiated carcinomas, six invasive papillary carcinomas, four mixed ductal-lobular carcinomas, three apocrine carcinomas, four medullary
carcinomas, three metaplastic carcinomas, two sarcomatoid carcinomas, two adenoid cystic carcinomas, and one case each of the following histological subtypes:
adenosquamous and neuroendocrine.
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primer pairs, 5% of mutant DNA in the template was
the lower limit of detection (Figure 1), indicating that
tumour samples containing at least 5% tumour cells
could be reliably screened by this method. This level of
sensitivity is in agreement with previously reported
HRM data [24].
EGFR mutation detection by high-resolution melting
analysis and sequencing in genomic DNA from TNBC
samples
The EGFR exon 19 (182-bp amplicon) and exon 21
(164-bp amplicon) primer pairs were used to screen the
229 TNBC DNA samples. All samples were successfully
amplified. To confirm the quality of the DNA (pre-
viously controlled by spectrometry), the number of
cycles needed to reach the fluorescence threshold (that
is, the cycle threshold (Ct) value) was measured. The
mean Ct value was 23.0 cycles (range, 18.9 to 25.7
cycles) for the 182-bp amplicon and 22.8 cycles (range,
19.8 to 25.3 cycles) for the 164-bp amplicon. The
absence of poor or late amplification confirmed the
quality of the DNA samples. The HRM curve analysis
allowed the identification of three abnormal profiles for
the EGFR exon 21 amplicon and none for the EGFR
exon 19 amplicon.
Bidirectional sequencing analysis was performed for all
229 DNA samples and confirmed the HRM results. A
synonymous SNP in EGFR exon 21 (c.2508C > T, p.
R836R) that corresponded to the SNP rs17290559 in the
National Center for Biotechnology Information (NCBI)
SNP database (National Institutes of Health, Bethesda,
MD, USA) was identified in the three samples with
altered HRM profiles. The 226 samples with HRM pro-
files similar to those of wild-type controls were con-
firmed as having wild-type EGFR by sequencing
analysis. No EGFR-activating mutation was found.
Discussion
Clinical studies are currently underway to evaluate the
efficacy of EGFR tyrosine kinase inhibitors in patients
with TNBC, because hormonal therapies and HER-2-tar-
geted agents are ineffective. The evaluation of the corre-
lation between EGFR-activating mutations and the
response of TNBC to EGFR targeted therapies, as well
as the determination of the percentage of patients who
might harbour an EGFR-activating mutation in tumour
cells, are essential prerequisites for comprehensive clini-
cal development of EGFR tyrosine kinase inhibitor trials
in this setting.
Herein we report the results of EGFR mutational ana-
lysis of a large, comprehensive set of 229 European
TNBC patients by HRM analysis and bidirectional
sequencing. To the best of our knowledge, this is the
largest cohort of patients with TNBC in whom the
presence of EGFR-activating mutations has been investi-
gated. We found no activating mutations (exon 19 dele-
tions or the L858R substitution) in our 229 samples.
HRM is a high-throughput method for genotyping and
mutation scanning [25,26]. It allows detection of muta-
tions related to base substitution or base deletions with
high sensitivity and high specificity. The sensitivity and
specificity of HRM analysis is higher with DNA isolated
from frozen samples [27], and HRM results are also
accurate with regard to samples harbouring low-preva-
lence mutations [24,28]. The Ct values obtained during
the real-time PCR used for HRM assay confirmed the
quality of our DNA samples that were extracted from
freshly frozen tumours. One limitation of the HRM
assay is that the melting profiles of samples carrying
deletions do not show the same magnitude of change
observed with DNA harbouring heterozygous SNPs [29].
Moreover, depending on the SNP class, the melting
curve shifts are more or less important. Nevertheless,
we observed no discordance between HRM and sequen-
cing results. The C > T base change at codon 836 of
EGFR exon 21 is a class 1 SNP and was unambiguously
detected by HRM in three samples, whereas no T > G
substitution (class 2 SNP), which corresponds to the
EGFR L858R activating mutation, was detected. The
percentage of heterozygous genotypes in our TNBC ser-
ies is in agreement with the data in the NCBI SNP data-
base for the HapMap-CEU cohort (3.4%) and the exome
sequencing project cohort (2.8%). If we consider sequen-
cing the gold standard, our HRM test for detection of
EGFR mutations in exons 19 and 21 had 100% sensitiv-
ity and specificity. Although sequencing analysis cannot
be considered 100% accurate, owing to the low sensitiv-
ity of direct sequencing [30,31], the high tumour cellu-
larity after macrodissection, as well as the quality of the
DNA isolated from our frozen TNBC samples, allow us
to be confident in our results and to conclude that our
TNBC samples did not present EGFR-activating muta-
tions that are detectable using the routine techniques
used in molecular biology laboratories. A variation in
the percentage of tumour cells in the samples could not
explain the lack of detection of EGFR mutations in our
series based on the 5% sensitivity threshold of our HRM
test.
These results differ strikingly from those of the study
by Teng et al. [18], who recently reported the presence
of EGFR-activating mutations, particularly exon 19 dele-
tions and exon 21 missense (L858R) mutations, in 11.4%
of 70 TNBC samples from a cohort of 653 patients with
TNBC (the cutoff value for ER and PR positivity was
10% like in our study). Moreover, this frequency of
EGFR-activating mutations was higher than that
described in previous work. Bhargava et al. reported no
EGFR exon 19 in-frame deletions or exon 21 L858R
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Figure 1 Sensitivity for the EGFR high-resolution melting assays. Serial dilutions of mutant DNA in proportions of 50%, 25%, 10%, 5% and
2% were compared with the wild-type control sample (LNCaP cell DNA) to determine the sensitivity of the test. (A) Serial dilutions of genomic
DNA from the H1650 cell line were compared with the control sample to produce the difference plot for the 182-bp (exon 19) amplicon. (B)
Serial dilutions of genomic DNA from the H1975 cell line were compared with the control sample to produce the difference plot for the 164-bp
(exon 21) amplicon. HRM = high-resolution melting.
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point mutations in 11 EGFR-amplified sporadic breast
tumours, of which 8 were TNBC [32]. In the study by
Reis-Filho et al., no EGFR-activating mutation was iden-
tified in a group of 47 metaplastic breast carcinomas, a
subset of basal-like breast cancers in which EGFR is
overexpressed in 80% of the cases and amplified in
about one third of them [6]. Generali et al. identified
only EGFR silent mutations in 42 unselected sporadic
breast tumours [33]. Toyama et al. analysed 58 tumour
samples from Japanese patients with TNBC to detect 14
known EGFR mutations, including exon 19 deletions
and the exon 21 L858R mutation, but none was found
[34]. Lv et al. recently reported the presence of two
(1.4%) EGFR activating mutations in 139 Chinese
women with breast cancers (10 triple-negative tumours)
using RT-PCR (1 exon 19 deletion and 1 exon 21 L858R
mutation) [35]. The two mutations were in triple-nega-
tive ductal carcinoma and in ER-positive ductal carci-
noma. A higher rate of EGFR missense mutations
(45.8%) was reported in hereditary BRCA1/2 positive
breast tumours, which are typically triple-negative, than
in sporadic breast cancers (14.6%) [36]. However, these
were often silent rather than activating mutations.
Lamy et al. recently reported 4.7% artefactual muta-
tions in KRAS using formalin-fixed paraffin-embedded
colon cancer tissue samples [37]. As noted by Marchetti
et al., “These artifacts can easily be observed by carrying
out multiple PCR amplifications of very small amounts
of DNA, particularly if the DNA is isolated from paraf-
fin-embedded tissues” [38] (p. 526). This could be
another explanation for the discrepancies of the results
of the different studies and raises the question of the
impact of the processing methods on the outcomes of
mutational analyses. However, it is important to con-
sider that these artefacts concerned C®T/G®A substi-
tutions and not exon 19 deletions or exon 21 L858R
mutations. Thus it is unlikely that fixation artefacts
might entirely explain the different percentages of EGFR
mutations reported by the aforementioned researchers.
On the other hand, the different frequencies of EGFR-
activating mutations reported by Teng et al. [18], in our
present study and by other researchers could suggest, as
already clearly shown for NSCLC, geographic and ethnic
variations in the frequency of EGFR-activating mutations
[21,39,40]. Indeed, the population studied by Teng et al.
was predominantly Chinese, whereas the other studies
were focused mainly on Japanese, American or European
cohorts. The identification of geographic and/or ethnic
variations in the frequency of EGFR-activating mutations
in two distinct tumour types could also suggest the possi-
ble existence of specific environmental carcinogenic fac-
tors that might play a role in NSCLC and TNBC
development and/or progression in East Asian patients.
Conclusions
Herein we report EGFR mutational analysis in a set of
229 European patients with TNBC. To our knowledge,
this is the largest cohort of patients with TNBC in
whom the presence of EGFR-activating mutations has
been investigated. We found no activating mutation
(exon 19 deletion or L858R mutations) in our 229
tumour samples. The striking difference in mutational
frequency between our study (0%) and the work by
Teng et al. [18] (11.4%) could highlight the existence
of geographic and ethnic variations in the prevalence
of EGFR mutations in TNBC. These variations have
crucial implications for the design of clinical trials
involving anti-EGFR therapies in patients with TNBC,
particularly for the selection of the potential target
population.
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